Koneksa’s rare disease experience includes a variety of areas, and our internal R&D efforts also include a rare disease focus.
- Vital signs
As the industry leader in digital biomarkers, we can design and develop configurable digital biomarkers that help you answer your most critical questions. Our measurement tools are remotely monitored for operational integrity and patient compliance at home. Plus, with multilingual capabilities and a global footprint, our solution empowers you to connect with difficult-to-access patients wherever they are, thus easing not only patient burden, but also the burden of rare disease caregivers.
Think beyond your current endpoints to what digital technology can unleash.
We Are the Leaders in Developing Evidence-Backed Rare Disease Measurement Concepts
Koneksa is dedicated to helping all our rare disease partners go through the journey of identifying, developing, and validating meaningful measures. We recognize that what is meaningful to patients and clinicians may overlap in some ways and differ in others. That is why a shared understanding of the biomarker objective is important.
We routinely support patient working groups, expert review panels, and pilots to advance measurement concept development. Rare disease patients are, by definition, few in number, so ensuring you are collecting truly informative data is essential to your program and to patients. By collecting meaningful data in the context of patients’ daily lives — and more of it — you gain the sharp insights needed to accurately assess treatment effect.
Deep Experience, Broad Range
Through a flexible, innovative mindset and experience in a wide array of diseases and indications, we have developed the finely honed technical expertise needed to configure the right measures for your rare disease trial.
Our work includes 70+ standard measures deployed to 1,000+ global sites in 20+ disease areas. Our therapeutic experience includes glucose transporter type 1 deficiency syndrome (Glut1DS), hemophilia, Angelman syndrome, achondroplasia, Fabry disease, sickle cell disease, paroxysmal nocturnal hemoglobinuria (PNH), and ataxia. With our experience and technology, we can help you bring much-needed treatments to patient populations who sorely need them.